BRIEF-Alkermes submits supplemental new drug application to FDA
August 08, 2016 at 07:36 AM EDT
* Alkermes submits supplemental new drug application to FDA for two month dosing option of Aristada for treatment of schizophrenia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.